Comparison of sequential estimation in response-adaptive designs with and without covariate-adjustment

Eunsik Park^{1,a}

^aDepartment of Statistics, Chonnam National University, Korea

Abstract

Subjects on one side of the covariate population can be allocated to the inferior treatment when there is interaction between the covariate and treatment along with a response-adaptive (RA) design without covariate adjustment. An RA design allows a newly entered subject to have a better chance so that the subject is treated by a superior treatment based on cumulative information from previous subjects. A covariate-adjusted response-adaptive (CARA) is the same as RA design and additionally adjusts the allocation based on individual covariate information. A comparison has been made for the sequential estimation procedure with and without covariate adjustment to see how ignoring significantly interactive covariate affects the correct treatment allocation. Using logistic models, we present simulation results regarding the coverage probability of treatment effect, correct allocation, and stopping time.

Keywords: covariate-adjustment, response-adaptive design, sequential estimation, stopping time

1. Introduction

In a response-adaptive (RA) design (Hu and Rosenberger, 2006; Zelen and Wei, 1995), the information collected from previously entered subjects is used and adjusts the allocation probability such that a newly entered subject can have a better chance for a superior treatment. The RA design serves ethical needs in performing clinical trials by allocating less numbers of subjects to inferior treatment. The sequential characteristic in this allocation process makes sequential statistical methods a natural choice for an RA design.

It is reasonable to additionally incorporate the available individual information of covariates that may affect responses if it is associated with treatments. We call this a covariate-adjusted response-adaptive (CARA) design. For example, the the RA design may assign subjects to the wrong treatment if an interaction exists between treatment and covariate.

A comparison has been made for the sequential estimation procedure with and without covariate adjustment to see how ignoring significantly interactive covariate affects the treatment allocation. The rest of this paper is organized as follows. Section 2 describes a sequential estimation procedure for treatment effect. Section 3 presents simulation studies and real examples applied to logistic models and Section 4 provides the conclusion.

¹ Department of Statistics, Chonnam National University, 77, Yongbong-ro, Buk-gu, Gwangju 61186, Korea.
E-mail: espark02@gmail.com

2. Sequential estimation of treatment effect in CARA designs

Hu and Rosenberger (2006) show that it is rare to find literature regarding applying stopping rules proposed for sequential estimation procedure based on CARA design despite the characteristics of CARA design that make it a natural sequential problem. Chang and Park (2013) proposed a sequential procedure described in this section to estimate the treatment effect under a CARA design. They estimated the treatment effects under a CARA design in a clinical trial such that the estimates satisfy a prescribed precision, while the number of subjects allocated to the superior treatment can be maximized without dimming the quality and efficiency to estimate treatment effects.

Suppose that $X_1, X_2, \dots$ is the sequence of random treatment assignments, and $X_m = (X_{m,1}, \dots, X_{m,K})$, $X_{m,k} \in \{0, 1\}$, denotes assignment of treatment k to m^{th} subject. Then $X_{m,k} = 1$ for some k and $\sum_{k=1}^K X_{m,k} = 1$. That is, each subject is allocated to one treatment only. Let $N_{m,k}$ be the number of subjects assigned to treatment k during the first m assignments. Suppose that $\{Y_{m,k}, m = 1, 2, \dots, k = 1, \dots, K\}$ denotes responses of m^{th} subject to k^{th} treatment. Let ξ_m be covariates of m^{th} subject. Assume the allocation function $\pi(\cdot, \cdot) = (\pi_1(\cdot, \cdot), \dots, \pi_K(\cdot, \cdot))$ with $\sum_{k=1}^K \pi_k = 1$ and $0 < \nu_k = E_\xi[\pi_k(\theta, \xi)] < 1$, $k = 1, \dots, K$. Assume further that for fixed ξ , $\pi_k(\theta, \xi) > 0$ is a continuous function of θ and is differentiable with respect to θ such that $\nu_k(\tilde{\theta}) = \nu_k(\theta) + (\tilde{\theta} - \theta)(\partial \nu_k / \partial \theta)' + o(\|\tilde{\theta} - \theta\|^{1+\zeta})$ for some $\zeta > 0$, and let $\nu = (\nu_1, \dots, \nu_K)$. Suppose that for each $m \geq 1$, the responses and covariates satisfy

$$E[Y_{m,k} | \xi_m] = \mu_k(\theta_k, \xi_m), \quad (2.1)$$

where $\mu_k(\cdot, \cdot)$, $k = 1, \dots, K$, are known functions, and let $V = \text{diag}\{V_1, \dots, V_K\}$ where V_k denotes the covariance matrix based on equation (2.1). Hence, it follows from equation (2.1) and V that the method of generalized linear models can be applied according to McCullagh and Nelder (1989).

2.1. The sequential procedure with the stopping rule

The effective sample size for a clinical trial with adaptive design is usually unavailable. Hence, the sequential method, which allows the sample size to be determined based on the observed information, is therefore an adequate choice to make an efficient and valid statistical inference. A sequential method is also a natural choice in an RA design since the treatment allocation process itself is sequential, and its stopping rule is described in this section.

Assume that $\theta_k \in \Theta_k \subseteq R^p$ for $k = 1, \dots, K$, and let the parameter space $\Theta = \prod_{k=1}^K \Theta_k$. Under the above assumptions (also Condition A of Zhang *et al.* (2007), Theorem 2.1), asymptotic normality of $\hat{\theta}$ is proved that as $\min(N_{m,k}, k = 1, \dots, K)$ goes to infinity. $\hat{\theta}$ is the maximum quasi-likelihood estimate of θ based on previous observations. See Section A.1 of Chang and Park (2013) for details on the estimation procedure. The confidence set of $\theta = (\theta_1, \dots, \theta_K)$ is therefore defined to be

$$R_\delta = \left\{ \theta \in \Theta : n(\hat{\theta} - \theta)' V^{-1} (\hat{\theta} - \theta) \leq C_\alpha^2 \right\},$$

where C_α^2 is the constant such that $P(\chi^2(p \cdot K) \geq C_\alpha^2) \leq \alpha$. R_δ denotes the confidence ellipsoid for given δ . Suppose we require that the maximum axis of R_δ ($\delta > 0$) be no larger than 2δ to control its size. The constant δ here is, therefore, used as a measure of precision of the confidence ellipsoid R_δ . The minimum sample size to achieve this goal is

$$n\Lambda_{\min}(V^{-1}) \geq \frac{C_\alpha^2}{\delta^2},$$

where $\Lambda_{\min}(A)$ and $\Lambda_{\max}(A)$ are the minimum and maximum eigenvalues of matrix A . Thus the corresponding optimal sample size is

$$n_{opt} = \text{first } n \text{ such that } n \geq \frac{C_\alpha^2 \Lambda_{\max}(V)}{\delta^2}. \quad (2.2)$$

Once V in equation (2.2) is estimated consistently by $\hat{V}$, a stopping rule for a fixed size confidence ellipsoid is suggested:

$$\begin{aligned} \tau_\delta &= \text{first } n \text{ such that } n \geq \frac{C_\alpha^2 \Lambda_{\max}(\hat{V})}{\delta^2} \\ &= \inf \left\{ n \geq n_0 : n \geq \frac{C_\alpha^2 \Lambda_{\max}(\hat{V})}{\delta^2} \right\}, \end{aligned} \quad (2.3)$$

where $n_0 \geq Km_0$ is the minimum initial sample size and m_0 is the initial sample size for each treatment.

Chang and Park (2013) showed that $\hat{\theta}$ have the same asymptotic distribution if we replace the fixed sample size with a random sample size τ_δ under the CARA design. They also showed that the same asymptotic property holds when we are interested in contrasts of parameters. For example, we are interested in estimating differences between treatment groups rather than estimating individual treatment effects.

2.2. Treatment allocation

In order to allocate more patients to the better treatment, Bandyopadhyay *et al.* (2007) suggests using the utility function below. They used this function under the CARA scheme for the two-stage design with binary responses.

Treatment allocation is implemented via the utility function, for K treatments defined as

$$U(p) = \log |\hat{I}_{n+1}| - \eta \left\{ \sum_{k=1}^K p_k \log \left(\frac{p_k}{\pi_k(\hat{\theta}, \xi)} \right) \right\}, \quad (2.4)$$

where $\pi_k(\hat{\theta}, \xi)$ is the estimate of $\pi_k(\theta, \xi)$ denoting the estimate of the allocation probability for treatment k up to the current stage n , and $\hat{I}_{n+1}$ is the estimate of Fisher information with a newly added subject and n number of subjects up to the current stage. For a given covariate ξ and the current estimate of θ , the optimal allocation rule is to find the vector of allocation probabilities $p = (p_1, \dots, p_K)$ that maximize the utility function above. That is, we allocate the $(n+1)^{th}$ subject to the treatment that maximizes the utility function; treatment allocation proportions are different so that the better treatment is allocated more often.

In the utility function, the first term depends on the information matrix. If $\eta = 0$, then the new subject is selected to maximize the Fisher information matrix. However, if η goes to ∞ , then the optimal value of p is to maximize the relative entropy function, the second term of equation (2.4). Hence, the parameter η can be used to adjust the ethical and efficiency balance. Here we adopt the idea of a utility function to balance the needs for the estimation precision of treatment effects and the ethical consideration. Bandyopadhyay *et al.* (2007) showed some asymptotic properties of p_k s theoretically along with some numerical results for various η s.

$\pi_k(\hat{\theta}, \xi)$, the second term in the utility function, can vary sequentially through T_n at each allocation. For example, Chang and Park (2013) defined $\pi_k(\hat{\theta}, \xi)$ as follows with $K = 2$ for illustration purposes.

$$\pi_1(\hat{\theta}, \xi) = J\left(\frac{\xi' \hat{\theta}_1 - \xi' \hat{\theta}_2}{T_n}\right) \quad \text{and} \quad \pi_2(\hat{\theta}, \xi) = 1 - \pi_1(\hat{\theta}, \xi),$$

where $J(t)$ is to be positive non-trivial symmetric with respect to origin and integrable with respect to the distribution of ξ . Both T_n and η can serve as tuning parameters between efficiency and ethics and be random depending on the estimate's precision. T_n can be a function of standard deviation of the treatment effect estimate based on cumulative observations up to n^{th} subject. Please note that T_n and η are also tuned by a new covariate ξ of the $(n + 1)^{\text{th}}$ subject.

By altering the parameters of the utility function in a utility function, at the beginning stage of a study, we can make more efforts to improve stability of treatment effects in terms of estimation precision. Once the estimate of treatment effects becomes stable as the sample size becomes large, we may assign more attention to the ethical part at the later stage of the study. We also tend to allocate more patients for the better treatment if there is sufficient information on treatment effects. The utility function facilitates the need for both the estimating treatment effects and the ethical consideration to be fulfilled and balanced accordingly.

3. Numerical study

The numerical study compares the performance of the estimate of the treatment effect and the allocation of subjects depending on whether the covariate interacting with treatment group is ignored in the treatment allocation process or not. In order to apply the sequential confidence estimation procedure, for K treatments, and treatment allocation procedures in Section 2, for illustration purposes, we consider a binary response case in this study using the logistic model.

3.1. Application to logistic models

Suppose $Y_k = 1(0)$ denotes a response variable with success (failure) from a subject assigned to treatment k for $k = 1, \dots, K$. Let $\mu_k(\theta_k, \xi) = E[Y_k = 1|\xi]$, and $\theta_k = (\alpha_k, \theta_k^*)$. Assume that

$$\text{logit}(\mu_k(\theta_k, \xi)) = \alpha_k + \theta_k^* \xi, \quad k = 1, \dots, K. \quad (3.1)$$

The covariate vector can be redefined as $(1, \xi)'$, without loss of generality; therefore, we assume that $\alpha_k = 0$, $k = 1, \dots, K$. Suppose there are m_0 initial samples for each treatment and assume that we are at the m^{th} stage with $m > Km_0$.

We then compare the performance of the estimate of the treatment effect and the allocation of subjects of the two numerical studies to illustrate the importance of considering the covariate in the treatment allocation when it significantly interacts with the treatment groups.

3.2. Simulation study

The same parameter setup is made to compare our simulation results when the covariate is ignored as the one by Chang and Park (2013) when the covariate is considered in the treatment allocation.

We assume logistic models with binary responses, treatments A and B and one continuous covariate X . In the logistic models, we assume equal intercepts for both treatments $(\alpha_A, \alpha_B) = (0.1, 0.1)$ and regression coefficients $(\beta_A, \beta_B) = (-1, 1)$. The covariate is generated from a mixed normal distribution with means 2 & -2 and equal variance 1 with respective probability 0.5 (Figure 1 of Chang and

Park (2013)). The treatment effect is defined as a function of differences of intercepts and regression coefficients between the two treatments; therefore, we apply the stopping rule for the contrasts of parameters, $\gamma = H'\theta$. The transpose of the contrast H is then defined as a matrix with its first row $(1, -1, 0, 0)$ and its second row $(0, 0, 1, -1)$, and the vector of parameters θ is $(\alpha_A, \alpha_B, \theta_A^*, \theta_B^*)'$.

Precision δ is assumed 0.3 and initial sample size for each treatment, m_0 , is assumed as 5, 10, and 15. Several combinations of tuning parameters T_n and η are assumed: 0.5, 1 and 2 for T_n and 0, 0.1 and 1 for η . Both fixed and varying tuning parameters, T_n and η , are considered; that is, T_n and η are fixed until the study stops, or vary whenever a new observation is added in a way that T_n is proportional and η is inversely proportional to the standard deviation of the treatment effect for a given covariate of a new observation. Findings from simulation studies are as follows (Table 1).

Here are findings from the numerical results when the covariate is ignored; stopping time is 30 if $2m_0 = 30$, same as the total initial sample sizes, 28 if $2m_0 = 20$ or if $2m_0 = 10$ and $\eta = 0.0$, and larger than 28 if $2m_0 = 10$ and $\eta = 0.1$ or 1.0, i.e., stopping time is very early and similar unless initial sample size is very small with positive η . Varying η or T_n do not make differences in terms of stopping time. Stopping time is very stable unless initial sample size m_0 is small, such as 5, where regression coefficient estimates are unstable at the beginning stage. The coverage probabilities of treatment differences cannot be computed because the covariate is ignored. Instead, coverages of intercept differences are given in Table 1 and are mostly larger than the nominal level 0.95 and become closer to 1 as the initial sample size m_0 gets larger, because there are less additional samples collected for larger m_0 .

Correct allocation probabilities are mostly close to 0.5, since the covariate is distributed symmetrically on both sides of intersection as in Figure 1 of Chang and Park (2013), in which varying η or T_n do not make any differences. This confirms that response-adaptive allocation ignoring significantly interacting covariate with treatment groups does not play an ethical role by failing to skew the allocation for better treatment group.

3.3. Illustrative example

It is not easy to find real data obtained from the CARA design; therefore, we present to illustrate a real example by modifying the study that applied non-response-adaptive design of Van Cutsem *et al.* (2009) into the CARA design but employing the same relationship between covariate, treatment group, and the response variable as one in this work. In this study, patients with epidermal growth factor receptor-positive colorectal cancer with unresectable metastases were randomly assigned to receive FOLFIRI either alone or in combination with cetuximab. They conducted a retrospective subgroup analysis to investigate the influence of the tumor KRAS mutation status on tumor response. There was a significant interaction between the treatment group and KRAS mutation status for tumor response when analyzed using the logistic regression model ($p = 0.03$). The adjusted odds ratio for a tumor response with cetuximab plus FOLFIRI treatment, as compared to FOLFIRI alone, was 1.40 (95% CI, 1.12 to 1.77; $p = 0.004$) (Figure 2B in Van Cutsem *et al.* (2009)). For each KRAS mutation status, number of tumor responses and the odds ratios along with their confidence intervals are given in Table 2 (Chang and Park, 2013).

This study was performed under the random treatment allocation; however, we simulate a situation as if it were done under the CARA design. We assume logistic models with binary tumor responses, two treatment groups and one binary covariate, KRAS status. In the logistic model, intercepts and regression coefficients are chosen so that the same odds ratios as in Van Cutsem *et al.* (2009) are achieved (Table 2)

The treatment effect is defined as a function of differences of intercepts and regression coefficients

Table 1: Mean (M) and standard deviation (SD) of stopping time (τ_{δ_y}), coverage probability (CP) and correct allocation probability (CAP) of sequential 95% confidence interval estimation with $\delta = 0.3$ when the covariate interacting with treatment groups is ignored in the treatment allocation process

m_0	T_n	η	Variation		τ_{δ_y}				m_0	T_n	η	Variation		τ_{δ_y}			
			T_{nV}	η_V	M	SD	CP	CAP				T_{nV}	η_V	M	SD	CP	CAP
5	0.5	0.0	N	N	28	1	1.00	0.50	10	1.0	0.1	Y	Y	28	2	0.99	0.50
5	0.5	0.0	Y	N	28	1	1.00	0.50	10	1.0	1.0	N	N	28	4	0.99	0.50
5	0.5	0.1	N	N	36	18	0.96	0.50	10	1.0	1.0	N	Y	28	3	1.00	0.49
5	0.5	0.1	N	Y	38	21	0.93	0.50	10	1.0	1.0	Y	N	28	2	0.99	0.49
5	0.5	0.1	Y	N	36	16	0.96	0.50	10	1.0	1.0	Y	Y	28	2	1.00	0.49
5	0.5	0.1	Y	Y	35	15	0.97	0.50									
5	0.5	1.0	N	N	39	20	0.94	0.50	10	2.0	0.0	N	N	28	1	1.00	0.51
5	0.5	1.0	N	Y	38	18	0.95	0.50	10	2.0	0.0	Y	N	28	1	1.00	0.49
5	0.5	1.0	Y	N	39	19	0.95	0.50	10	2.0	0.1	N	N	28	1	1.00	0.49
5	0.5	1.0	Y	Y	38	18	0.95	0.50	10	2.0	0.1	N	Y	28	1	1.00	0.50
									10	2.0	0.1	Y	N	28	1	1.00	0.50
5	1.0	0.0	N	N	28	1	1.00	0.50	10	2.0	0.1	Y	Y	28	2	1.00	0.49
5	1.0	0.0	Y	N	28	1	1.00	0.50	10	2.0	1.0	N	N	28	1	1.00	0.50
5	1.0	0.1	N	N	31	12	0.98	0.50	10	2.0	1.0	N	Y	28	1	1.00	0.50
5	1.0	0.1	N	Y	31	10	0.98	0.50	10	2.0	1.0	Y	N	28	2	1.00	0.50
5	1.0	0.1	Y	N	29	4	0.99	0.50	10	2.0	1.0	Y	Y	28	1	1.00	0.49
5	1.0	0.1	Y	Y	30	5	0.99	0.51									
5	1.0	1.0	N	N	33	16	0.96	0.50	15	0.5	0.0	N	N	30	0	1.00	0.54
5	1.0	1.0	N	Y	35	17	0.95	0.50	15	0.5	0.0	Y	N	30	0	1.00	0.55
5	1.0	1.0	Y	N	31	7	0.99	0.50	15	0.5	0.1	N	N	30	0	1.00	0.38
5	1.0	1.0	Y	Y	31	9	0.98	0.49	15	0.5	0.1	N	Y	30	0	1.00	0.57
									15	0.5	0.1	Y	N	30	1	1.00	0.53
5	2.0	0.0	N	N	28	1	1.00	0.50	15	0.5	0.1	Y	Y	30	1	1.00	0.37
5	2.0	0.0	Y	N	28	1	1.00	0.50	15	0.5	1.0	N	N	30	0	1.00	0.46
5	2.0	0.1	N	N	28	3	0.99	0.50	15	0.5	1.0	N	Y	30	0	1.00	0.64
5	2.0	0.1	N	Y	28	3	0.99	0.50	15	0.5	1.0	Y	N	30	0	1.00	0.52
5	2.0	0.1	Y	N	28	1	1.00	0.50	15	0.5	1.0	Y	Y	30	0	1.00	0.39
5	2.0	0.1	Y	Y	28	2	0.99	0.50									
5	2.0	1.0	N	N	29	5	1.00	0.50	15	1.0	0.0	N	N	30	0	1.00	0.50
5	2.0	1.0	N	Y	29	6	0.99	0.49	15	1.0	0.0	Y	N	30	1	1.00	0.47
5	2.0	1.0	Y	N	29	3	0.99	0.50	15	1.0	0.1	N	N	30	0	1.00	0.43
5	2.0	1.0	Y	Y	29	3	0.99	0.50	15	1.0	0.1	N	Y	30	2	1.00	0.31
									15	1.0	0.1	Y	N	30	0	1.00	0.36
10	0.5	0.0	N	N	28	1	1.00	0.50	15	1.0	0.1	Y	Y	30	0	1.00	0.38
10	0.5	0.0	Y	N	28	1	1.00	0.48	15	1.0	1.0	N	N	30	1	1.00	0.42
10	0.5	0.1	N	N	29	4	1.00	0.50	15	1.0	1.0	N	Y	30	1	1.00	0.58
10	0.5	0.1	N	Y	29	3	0.99	0.49	15	1.0	1.0	Y	N	30	0	1.00	0.23
10	0.5	0.1	Y	N	29	5	0.99	0.50	15	1.0	1.0	Y	Y	30	0	1.00	0.30
10	0.5	0.1	Y	Y	29	4	0.99	0.49									
10	0.5	1.0	N	N	29	4	0.99	0.49	15	2.0	0.0	N	N	30	0	1.00	0.56
10	0.5	1.0	N	Y	29	5	0.99	0.49	15	2.0	0.0	Y	N	30	0	1.00	0.48
10	0.5	1.0	Y	N	29	3	0.99	0.51	15	2.0	0.1	N	N	30	0	1.00	0.32
10	0.5	1.0	Y	Y	29	2	0.99	0.50	15	2.0	0.1	N	Y	30	0	1.00	0.41
									15	2.0	0.1	Y	N	30	0	1.00	0.56
10	1.0	0.0	N	N	28	1	1.00	0.49	15	2.0	0.1	Y	Y	30	0	1.00	0.35
10	1.0	0.0	Y	N	28	1	1.00	0.50	15	2.0	1.0	N	N	30	0	1.00	0.59
10	1.0	0.1	N	N	28	3	0.99	0.50	15	2.0	1.0	N	Y	30	0	1.00	0.35
10	1.0	0.1	N	Y	28	2	0.99	0.50	15	2.0	1.0	Y	N	30	0	1.00	0.29
10	1.0	0.1	Y	N	28	2	0.99	0.50	15	2.0	1.0	Y	Y	30	0	1.00	0.66

T_{nV} and η_V indicate whether T_n and η vary or not.

Table 2: Tumor response summary to cetuximab plus FOLFIRI vs FOLFIRI alone treatment by KRAS status

Tumor response	Cetuximab plus FOLFIRI		FOLFIRI alone		Odds ratio
	Yes	No	Yes	No	
KRAS population	140	137	111	152	1.38 (0.98–1.95)
Mutant KRAS	38	67	35	52	0.80 (0.44–1.45)
Wild-type KRAS	102	70	76	100	1.91 (1.24–2.93)

between the two treatments; therefore, we apply the stopping rule for the contrasts of parameters, $\gamma = H'\theta$, given in Section 2.2 of Chang and Park (2013). Here, the transpose of the contrast H is defined as a matrix with its first row $(1, -1, 0, 0)$ and its second row $(0, 0, 1, -1)$, and the vector of parameters θ is $(\alpha_A, \alpha_B, \theta_A^*, \theta_B^*)'$.

Precision δ is assumed 0.2 and initial sample size for each treatment, m_0 , is assumed as 15, 20, and 25. Several combinations of tuning parameters T_n and η are assumed: 0.1, 0.3 and 0.5 for T_n and 0, 0.01 and 0.1 for η . Both fixed and varying tuning parameters, T_n and η , are considered; that is, T_n and η are fixed until the study stops, or vary whenever a new observation is added in a way that T_n is proportional and η is inversely proportional to the standard deviation of the treatment effect for a given covariate of a new observation. Findings from simulation results when the KRAS status is considered are as follows (Table 3).

As η gets larger, stopping time gets later but its increase is reduced as initial sample size gets larger. Varying η or T_n does not give significantly different results compared to fixed values. Stopping time is later and more unstable as η is larger or initial sample size m_0 is smaller, due to unstable regression coefficient estimates at the beginning stage. The coverage probabilities of treatment differences becomes closer to 0.95 as the initial sample size m_0 gets larger and η gets smaller.

For wild-type KRAS population, as η gets larger, if $T_n = 0.3$ and 0.5, correct treatment allocation gets better with similar performance for positive η . This confirms that η plays a role as a tuning parameter for ethical consideration and a small, nonzero η is sufficient for correct allocation. However, if $T_n = 0.1$, correct treatment allocation gets worse for positive η and when T_n is varying. $T_n = 0.1$ is too small to secure accurate treatment estimate and subsequently inflate small treatment effect in the utility function to make wrong treatment allocation. For small T_n , non-increasing sensitivities are due to giving too much weight to ethical side by increasing η before getting accurate estimates of treatment effect. This implies that we do not need to sacrifice accuracy by increasing η . Small positive η is adequate to provide the ethical emphasis. CAP also greatly decreases when T_n is 0.1 and variable due to smaller T_n than 0.1 for varying T_n .

For mutant KRAS population, correct allocation is better when $\eta = 0.01$ compared to $\eta = 0.00$. However it is mostly not increased when η is increased from 0.01 to 0.1. This is also due to too much weight to the ethical side assigning large η before estimating accurate treatment effect. Treatment allocation is best if $T_n = 0.1$ for mutant KRAS because of easy detection of small treatment differences (odds ratio is small, 0.80, for mutant KRAS while it is large, 1.91, for wild-type KRAS). If we have to use the same T_n for both KRAS status, then $T_n = 0.3$ or 0.5 are recommended because differences of correct allocation are larger when $T_n = 0.3$ or 0.5 compared to $T_n = 0.1$ for each KRAS status. In summary, small positive η is adequate for ethical consideration and reasonable sized T_n is recommended for correct allocation because too small T_n may yield decreasing correct allocation from 0.5 as η is increased. Varying η does not affect the correct allocation seriously but varying too small T_n may decrease correct allocation greatly to smaller than 0.5.

Findings from the numerical results when KRAS status is ignored are as follows (Table 4). Stopping time is 50 if $2m_0 = 50$, same as the total initial sample sizes, mostly 40 if $2m_0 = 40$ or if $2m_0 = 30$, i.e., stopping time is very early and similar. Varying η or T_n do not make differences in

Table 3: Mean (M) and standard deviation (SD) of stopping time (τ_{δ_y}), coverage probability (CP) and correct allocation probabilities (CAP) of sequential 95% confidence interval estimation with $\delta = 0.2$ when the covariate interacting with treatment groups is considered in the treatment allocation process

m_0	T_n	η	Variation		τ_{δ_y}					m_0	T_n	η	Variation		τ_{δ_y}				
			T_{nV}	η_V	M	SD	CP	CAP _w	CAP _m				T_{nV}	η_V	M	SD	CP	CAP _w	CAP _m
15	0.1	0.00	N	N	131	6	0.98	0.51	0.52	20	0.3	0.01	Y	Y	169	41	0.90	0.81	0.61
15	0.1	0.00	Y	N	132	11	0.97	0.51	0.52	20	0.3	0.10	N	N	173	36	0.88	0.86	0.63
15	0.1	0.01	N	N	199	63	0.87	0.45	0.73	20	0.3	0.10	N	Y	184	55	0.92	0.83	0.55
15	0.1	0.01	N	Y	199	75	0.86	0.44	0.70	20	0.3	0.10	Y	N	183	42	0.90	0.84	0.60
15	0.1	0.01	Y	N	204	81	0.83	0.24	0.71	20	0.3	0.10	Y	Y	186	41	0.88	0.88	0.54
15	0.1	0.01	Y	Y	210	72	0.83	0.23	0.74										
15	0.1	0.10	N	N	228	96	0.85	0.45	0.76	20	0.5	0.00	N	N	131	8	0.96	0.50	0.53
15	0.1	0.10	N	Y	219	90	0.88	0.45	0.73	20	0.5	0.00	Y	N	131	6	0.99	0.50	0.54
15	0.1	0.10	Y	N	227	95	0.83	0.20	0.70	20	0.5	0.01	N	N	142	20	0.91	0.69	0.60
15	0.1	0.10	Y	Y	211	78	0.86	0.20	0.72	20	0.5	0.01	N	Y	144	23	0.92	0.74	0.55
										20	0.5	0.01	Y	N	150	26	0.92	0.81	0.60
15	0.3	0.00	N	N	130	7	0.98	0.51	0.53	20	0.5	0.01	Y	Y	151	25	0.94	0.82	0.59
15	0.3	0.00	Y	N	131	9	0.97	0.51	0.53	20	0.5	0.10	N	N	165	41	0.86	0.83	0.53
15	0.3	0.01	N	N	156	36	0.90	0.77	0.57	20	0.5	0.10	N	Y	161	42	0.93	0.82	0.58
15	0.3	0.01	N	Y	167	62	0.86	0.78	0.55	20	0.5	0.10	Y	N	162	30	0.92	0.82	0.60
15	0.3	0.01	Y	N	172	42	0.87	0.84	0.58	20	0.5	0.10	Y	Y	174	41	0.87	0.82	0.51
15	0.3	0.01	Y	Y	183	51	0.80	0.80	0.65										
15	0.3	0.10	N	N	197	58	0.84	0.85	0.58	25	0.1	0.00	N	N	131	7	0.97	0.50	0.55
15	0.3	0.10	N	Y	206	61	0.82	0.81	0.57	25	0.1	0.00	Y	N	131	7	0.99	0.50	0.55
15	0.3	0.10	Y	N	198	71	0.90	0.83	0.59	25	0.1	0.01	N	N	152	18	0.98	0.53	0.62
15	0.3	0.10	Y	Y	210	83	0.82	0.82	0.61	25	0.1	0.01	N	Y	162	27	0.93	0.50	0.69
										25	0.1	0.01	Y	N	157	22	0.96	0.28	0.72
15	0.5	0.00	N	N	131	8	0.99	0.51	0.53	25	0.1	0.01	Y	Y	159	24	0.98	0.28	0.75
15	0.5	0.00	Y	N	130	7	1.00	0.51	0.52	25	0.1	0.10	N	N	164	25	0.94	0.48	0.68
15	0.5	0.01	N	N	146	34	0.93	0.70	0.53	25	0.1	0.10	N	Y	163	23	0.97	0.52	0.63
15	0.5	0.01	N	Y	154	37	0.86	0.72	0.58	25	0.1	0.10	Y	N	162	24	0.94	0.23	0.65
15	0.5	0.01	Y	N	160	41	0.86	0.79	0.58	25	0.1	0.10	Y	Y	163	28	0.98	0.28	0.75
15	0.5	0.01	Y	Y	164	41	0.81	0.79	0.58										
15	0.5	0.10	N	N	166	40	0.90	0.79	0.55	25	0.3	0.00	N	N	132	7	0.98	0.50	0.54
15	0.5	0.10	N	Y	180	47	0.84	0.78	0.54	25	0.3	0.00	Y	N	131	6	0.99	0.50	0.55
15	0.5	0.10	Y	N	174	40	0.91	0.83	0.54	25	0.3	0.01	N	N	145	18	0.92	0.79	0.56
15	0.5	0.10	Y	Y	181	46	0.89	0.86	0.55	25	0.3	0.01	N	Y	152	31	0.94	0.84	0.61
										25	0.3	0.01	Y	N	150	19	0.99	0.78	0.62
20	0.1	0.00	N	N	131	8	0.98	0.50	0.54	25	0.3	0.01	Y	Y	156	23	0.94	0.83	0.59
20	0.1	0.00	Y	N	132	8	0.96	0.50	0.55	25	0.3	0.10	N	N	163	30	0.96	0.86	0.57
20	0.1	0.01	N	N	174	35	0.90	0.47	0.77	25	0.3	0.10	N	Y	164	33	0.95	0.85	0.54
20	0.1	0.01	N	Y	173	40	0.92	0.54	0.71	25	0.3	0.10	Y	N	167	27	0.94	0.85	0.54
20	0.1	0.01	Y	N	174	36	0.93	0.23	0.65	25	0.3	0.10	Y	Y	161	26	0.95	0.80	0.61
20	0.1	0.01	Y	Y	175	42	0.91	0.24	0.70										
20	0.1	0.10	N	N	177	40	0.95	0.51	0.65	25	0.5	0.00	N	N	131	8	0.96	0.49	0.53
20	0.1	0.10	N	Y	181	45	0.93	0.51	0.69	25	0.5	0.00	Y	N	131	6	0.97	0.50	0.54
20	0.1	0.10	Y	N	184	45	0.93	0.25	0.69	25	0.5	0.01	N	N	137	14	0.95	0.71	0.55
20	0.1	0.10	Y	Y	182	34	0.90	0.30	0.78	25	0.5	0.01	N	Y	139	13	0.94	0.74	0.58
										25	0.5	0.01	Y	N	139	12	0.98	0.76	0.59
20	0.3	0.00	N	N	134	11	0.96	0.50	0.52	25	0.5	0.01	Y	Y	145	22	0.94	0.84	0.56
20	0.3	0.00	Y	N	132	9	0.95	0.49	0.52	25	0.5	0.10	N	N	152	29	0.92	0.81	0.57
20	0.3	0.01	N	N	158	44	0.90	0.77	0.53	25	0.5	0.10	N	Y	153	26	0.96	0.84	0.61
20	0.3	0.01	N	Y	159	27	0.93	0.83	0.59	25	0.5	0.10	Y	N	155	23	0.89	0.85	0.54
20	0.3	0.01	Y	N	162	29	0.94	0.82	0.59	25	0.5	0.10	Y	Y	157	24	0.91	0.88	0.60

T_{nV} and η_V indicate whether T_n and η vary or not.

Table 4: Mean (M) and standard deviation (SD) of stopping time (τ_{δ_y}), coverage probability (CP) and correct allocation probabilities (CAP) of sequential 95% confidence interval estimation with $\delta = 0.2$ when the covariate interacting with treatment groups is ignored in the treatment allocation process

m_0	T_n	η	Variation		τ_{δ_y}				m_0	T_n	η	Variation		τ_{δ_y}			
			T_{nV}	η_V	M	SD	CAP _w	CAP _m				T_{nV}	η_V	M	SD	CAP _w	CAP _m
15	0.1	0.00	N	N	41	1	0.48	0.48	20	0.3	0.01	Y	Y	41	2	0.65	0.26
15	0.1	0.00	Y	N	41	2	0.48	0.49	20	0.3	0.10	N	N	41	1	0.82	0.11
15	0.1	0.01	N	N	42	4	0.45	0.53	20	0.3	0.10	N	Y	41	2	0.81	0.23
15	0.1	0.01	N	Y	42	2	0.50	0.51	20	0.3	0.10	Y	N	41	2	0.89	0.17
15	0.1	0.01	Y	N	42	2	0.37	0.67	20	0.3	0.10	Y	Y	41	1	0.76	0.28
15	0.1	0.01	Y	Y	42	3	0.27	0.75									
15	0.1	0.10	N	N	228	42	0.51	0.50	20	0.5	0.00	N	N	41	1	0.05	0.91
15	0.1	0.10	N	Y	219	43	0.45	0.57	20	0.5	0.00	Y	N	41	1	0.05	0.95
15	0.1	0.10	Y	N	227	42	0.34	0.66	20	0.5	0.01	N	N	41	2	0.65	0.20
15	0.1	0.10	Y	Y	211	42	0.34	0.70	20	0.5	0.01	N	Y	41	2	0.82	0.25
									20	0.5	0.01	Y	N	41	2	0.74	0.24
15	0.3	0.00	N	N	41	1	0.50	0.52	20	0.5	0.01	Y	Y	41	1	0.72	0.20
15	0.3	0.00	Y	N	41	1	0.51	0.50	20	0.5	0.10	N	N	41	2	0.82	0.23
15	0.3	0.01	N	N	42	3	0.69	0.30	20	0.5	0.10	N	Y	41	2	0.62	0.22
15	0.3	0.01	N	Y	42	3	0.65	0.38	20	0.5	0.10	Y	N	41	1	0.86	0.24
15	0.3	0.01	Y	N	42	2	0.62	0.37	20	0.5	0.10	Y	Y	41	2	0.72	0.33
15	0.3	0.01	Y	Y	43	3	0.65	0.32									
15	0.3	0.10	N	N	43	5	0.66	0.32	25	0.1	0.00	N	N	50	0	.	.
15	0.3	0.10	N	Y	43	4	0.59	0.41	25	0.1	0.00	Y	N	50	0	.	.
15	0.3	0.10	Y	N	43	3	0.73	0.27	25	0.1	0.01	N	N	50	0	.	.
15	0.3	0.10	Y	Y	43	3	0.67	0.31	25	0.1	0.01	N	Y	50	0	.	.
									25	0.1	0.01	Y	N	50	0	.	.
15	0.5	0.00	N	N	41	1	0.49	0.48	25	0.1	0.01	Y	Y	50	0	.	.
15	0.5	0.00	Y	N	41	1	0.49	0.50	25	0.1	0.10	N	N	50	0	.	.
15	0.5	0.01	N	N	42	2	0.60	0.42	25	0.1	0.10	N	Y	50	0	.	.
15	0.5	0.01	N	Y	41	2	0.60	0.35	25	0.1	0.10	Y	N	50	0	.	.
15	0.5	0.01	Y	N	42	3	0.62	0.42	25	0.1	0.10	Y	Y	50	0	.	.
15	0.5	0.01	Y	Y	42	3	0.62	0.34									
15	0.5	0.10	N	N	43	6	0.68	0.29	25	0.3	0.00	N	N	50	0	.	.
15	0.5	0.10	N	Y	42	3	0.62	0.38	25	0.3	0.00	Y	N	50	0	.	.
15	0.5	0.10	Y	N	42	4	0.67	0.37	25	0.3	0.01	N	N	50	0	.	.
15	0.5	0.10	Y	Y	44	18	0.68	0.30	25	0.3	0.01	N	Y	50	0	.	.
									25	0.3	0.01	Y	N	50	0	.	.
20	0.1	0.00	N	N	41	1	0.06	0.98	25	0.3	0.01	Y	Y	50	0	.	.
20	0.1	0.00	Y	N	41	2	0.09	0.87	25	0.3	0.10	N	N	50	0	.	.
20	0.1	0.01	N	N	41	1	0.38	0.56	25	0.3	0.10	N	Y	50	0	.	.
20	0.1	0.01	N	Y	41	1	0.39	0.63	25	0.3	0.10	Y	N	50	0	.	.
20	0.1	0.01	Y	N	41	1	0.20	0.97	25	0.3	0.10	Y	Y	50	0	.	.
20	0.1	0.01	Y	Y	41	1	0.24	0.71									
20	0.1	0.10	N	N	41	1	0.41	0.60	25	0.5	0.00	N	N	50	0	0.00	.
20	0.1	0.10	N	Y	41	1	0.33	0.57	25	0.5	0.00	Y	N	50	0	.	.
20	0.1	0.10	Y	N	41	1	0.28	0.72	25	0.5	0.01	N	N	50	0	.	.
20	0.1	0.10	Y	Y	41	2	0.22	0.81	25	0.5	0.01	N	Y	50	0	.	.
									25	0.5	0.01	Y	N	50	0	.	.
20	0.3	0.00	N	N	41	1	0.03	0.84	25	0.5	0.01	Y	Y	50	0	.	.
20	0.3	0.00	Y	N	41	1	0.04	0.85	25	0.5	0.10	N	N	50	0	.	.
20	0.3	0.01	N	N	41	2	0.75	0.28	25	0.5	0.10	N	Y	50	0	1.00	.
20	0.3	0.01	N	Y	41	1	0.78	0.14	25	0.5	0.10	Y	N	50	0	.	.
20	0.3	0.01	Y	N	41	1	0.72	0.26	25	0.5	0.10	Y	Y	50	0	1.00	0.00

T_{nV} and η_V indicate whether T_n and η vary or not.

terms of stopping time. The coverage probabilities of treatment differences cannot be computed because the covariate is ignored. Instead, coverages of intercept differences are given in Table 4 and are mostly larger than the nominal level 0.95 since there are less additional samples collected for larger m_0 .

Correct allocation probabilities (CAP) for $m_0 = 25$ are not computed since there are no additional samples collected after initial samples. CAPs for $m_0 = 20$ are not reliable since only one or two additional samples were collected after the initial stage. CAPs for $m_0 = 15$ are computed with the 11–14 additional samples and similar observations with the ones when the covariate is considered are found but with smaller CAPs. This is due to asymmetric distribution of KRAS population on both sides of intersection of two logistic curves for treatment effects not due to covariate consideration.

These findings also confirm that response-adaptive allocation ignoring significantly interacting covariate with treatment groups does not play an ethical role by failing to skew the allocation for the better treatment group.

4. Conclusion

When significant interaction between treatment and covariates is ignored, study stops earlier than expected once a few additional samples are collected. This makes it difficult to try skewed allocation for better treatment and results in wrong treatment allocation. Throughout the paper, we have demonstrated the importance of considering covariates that interact with the treatment allocation in a RA design. For a real-world practice, it is recommended to investigate whether there are some possible covariates interacting with the treatment for a RA design.

Acknowledgments

This study was financially supported by Chonnam National University, 2014.

References

- Bandyopadhyay U, Biswas A, and Bhattacharya R (2007). A covariate adjusted two-stage allocation design for binary responses in randomized clinical trials, *Statistics in Medicine*, **26**, 4386–4399.
- Chang YI and Park E (2013). Sequential estimation for covariate-adjusted response-adaptive designs, *Journal of the Korean Statistical Society*, **42**, 105–116.
- Hu F and Rosenberger WF (2006). *The Theory of the Response-Adaptive Randomization in Clinical Trials*, Wiley Inter Science, London.
- McCullagh P and Nelder JA (1989). *Generalized Linear Models* (2nd ed), Chapman and Hall, London, UK.
- Van Cutsem E, Köhne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, et al. (2009). Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer, *New England Journal of Medicine*, **360**, 1408–1417.
- Zelen M and Wei LJ (1995). Foreword. In N Flournoy and WF Rosenberger (Eds), *Adaptive Designs*, Institute of Mathematical Statistics, Hayward, CA.
- Zhang LX, Hu F, Cheung SH, and Chan WS (2007). Asymptotic properties of covariate-adjusted response-adaptive designs, *Annals of Statistics*, **35**, 1166–1182.

Received April 3, 2016; Revised July 16, 2016; Accepted July 21, 2016